Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target refers to a **pseudogene** related to the protein-coding gene *Chaperonin containing TCP1 subunit 6A* (CCT6A), a molecular chaperone involved in the correct folding of actin, tubulin, and other cytosolic proteins as part of the chaperonin-containing TCP1 complex (TRiC/CCT)[4][5][6]. The pseudogene itself does **not code** for a functional protein, lacks documented biological activity, and is **not considered a therapeutic target**. Sometimes, sequences for pseudogenes are annotated in databases, but unless explicitly shown to have biological function (e.g., as regulatory non-coding RNA), they do not participate in disease pathways or drug interactions[2]. If your goal is to identify a druggable or biologically relevant molecule, you should refer to the functional gene CCT6A rather than its pseudogene. Additional context and clarification: - The **Ensembl ID ENSG00000254482** maps to a pseudogene, not to the protein-coding gene. The functional gene (*CCT6A*) is encoded by ENSG00000146731[4]. - If your query intended to target the functional protein, refer to *Chaperonin containing TCP1 subunit 6A* (CCT6A), which is implicated in cell cycle, protein folding, and several cancer types as an oncogene[3][5][6]. - The pseudogene does not have known therapeutic utility, safety concerns, or biomarker relevance. Summary: The provided target is a pseudogene, not a protein, and therefore is **not a valid therapeutic target**. For research on function, disease implications, or pharmacology, consult information for *Chaperonin containing TCP1 subunit 6A (CCT6A)* and its canonical identifiers such as ENSG00000146731[4][5][6][2].
Not applicable; not a druggable target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chaperonin containing TCP1 subunit 6A pseudogene.